Real-World Outcomes Following Switching from Anti-TNF Reference Products to Biosimilars for the Treatment of Psoriasis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-World Outcomes Following Switching from Anti-TNF Reference Products to Biosimilars for the Treatment of Psoriasis
Authors
Keywords
-
Journal
JOURNAL OF DERMATOLOGICAL TREATMENT
Volume -, Issue -, Pages 1-29
Publisher
Informa UK Limited
Online
2022-10-28
DOI
10.1080/09546634.2022.2140569
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis
- (2021) Stefano Piaserico et al. BIODRUGS
- Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis
- (2021) Nikolai Loft et al. JAMA Dermatology
- Efficacy of switching from adalimumab originator to adalimumab biosimilar in moderate to severe psoriasis patients: A Real‐life experience in a tertiary referral centre
- (2021) Giuseppe Gallo et al. AUSTRALASIAN JOURNAL OF DERMATOLOGY
- A single-centre, observational, retrospective, real-life study evaluating adalimumab biosimilar ABP 501 in the treatment of plaque-type psoriasis and psoriatic arthritis in originator-naïve patients and in patients undergoing non-medical switch from originator
- (2021) A. Giunta et al. CURRENT MEDICAL RESEARCH AND OPINION
- The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems
- (2021) Tore K. Kvien et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Switching from one infliximab biosimilar (CT‐P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis
- (2020) P. Gisondi et al. BRITISH JOURNAL OF DERMATOLOGY
- The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
- (2020) Liese Barbier et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis
- (2020) Antonella Di Cesare et al. Dermatologic Therapy
- Effectiveness and safety of switching from originator to biosimilar adalimumab in patients with psoriasis
- (2020) Valdemar Wendelboe Nielsen et al. Dermatologic Therapy
- Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States
- (2019) A. Teeple et al. CURRENT MEDICAL RESEARCH AND OPINION
- Clinical experience with the etanercept biosimilar SB4 in psoriatic patients
- (2019) L. Pescitelli et al. International Journal of Clinical Pharmacy
- Effectiveness and safety of switching to biosimilar infliximab and etanercept in patients with psoriasis
- (2019) Tamara Lund et al. Dermatologic Therapy
- Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States
- (2019) A. Teeple et al. CURRENT MEDICAL RESEARCH AND OPINION
- Etanercept biosimilar SB 4 in the treatment of plaque‐type psoriasis and psoriatic arthritis: a single‐center, observational, retrospective, real‐life study
- (2019) A. Giunta et al. BRITISH JOURNAL OF DERMATOLOGY
- Biosimilars for the treatment of psoriasis
- (2019) Lluís Puig et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches
- (2018) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis
- (2018) A. Egeberg et al. BRITISH JOURNAL OF DERMATOLOGY
- Adherence to biologics in patients with psoriasis
- (2018) Lauren Seale et al. Expert Review of Clinical Immunology
- 815 - Long-Term Efficacy and Safety of CT-P13 after Switching from Originator Infliximab: Exploratory Subgroup Analyses in IBD in the Nor-Switch Extension Trial
- (2018) Kristin K. Joergensen et al. GASTROENTEROLOGY
- Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis. Data from the Psobiosimilars registry
- (2018) P. Gisondi et al. BRITISH JOURNAL OF DERMATOLOGY
- Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
- (2017) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The road from development to approval: evaluating the body of evidence to confirm biosimilarity
- (2017) Paul Declerck et al. RHEUMATOLOGY
- The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis
- (2016) Paolo Dapavo et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Biosimilars for psoriasis: preclinical analytical assessment to determine similarity
- (2015) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More